Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


The Influence of Metabolism on Drug Response in Cancer.

Zaal EA, Berkers CR.

Front Oncol. 2018 Nov 2;8:500. doi: 10.3389/fonc.2018.00500. eCollection 2018. Review.


CTGF/VEGFA-activated Fibroblasts Promote Tumor Migration Through Micro-environmental Modulation.

Wu W, Zaal EA, Berkers CR, Lemeer S, Heck AJR.

Mol Cell Proteomics. 2018 Aug;17(8):1502-1514. doi: 10.1074/mcp.RA118.000708. Epub 2018 Apr 18.


Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.


Proteomic and Metabolomic Analyses of Vanishing White Matter Mouse Astrocytes Reveal Deregulation of ER Functions.

Wisse LE, Penning R, Zaal EA, van Berkel CGM, Ter Braak TJ, Polder E, Kenney JW, Proud CG, Berkers CR, Altelaar MAF, Speijer D, van der Knaap MS, Abbink TEM.

Front Cell Neurosci. 2017 Dec 20;11:411. doi: 10.3389/fncel.2017.00411. eCollection 2017.


Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.

Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR.

Cancer Metab. 2017 Aug 29;5:7. doi: 10.1186/s40170-017-0169-9. eCollection 2017.


Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification.

Widjaja CE, Olvera JG, Metz PJ, Phan AT, Savas JN, de Bruin G, Leestemaker Y, Berkers CR, de Jong A, Florea BI, Fisch K, Lopez J, Kim SH, Garcia DA, Searles S, Bui JD, Chang AN, Yates JR 3rd, Goldrath AW, Overkleeft HS, Ovaa H, Chang JT.

J Clin Invest. 2017 Oct 2;127(10):3609-3623. doi: 10.1172/JCI90895. Epub 2017 Aug 28.


Metabolic response of porcine colon explants to in vitro infection by Brachyspira hyodysenteriae: a leap into disease pathophysiology.

Welle T, Hoekstra AT, Daemen IAJJM, Berkers CR, Costa MO.

Metabolomics. 2017;13(7):83. doi: 10.1007/s11306-017-1219-6. Epub 2017 May 30.


Proteasome Activation by Small Molecules.

Leestemaker Y, de Jong A, Witting KF, Penning R, Schuurman K, Rodenko B, Zaal EA, van de Kooij B, Laufer S, Heck AJR, Borst J, Scheper W, Berkers CR, Ovaa H.

Cell Chem Biol. 2017 Jun 22;24(6):725-736.e7. doi: 10.1016/j.chembiol.2017.05.010. Epub 2017 May 25.


TGFβ1-induced leucine limitation uncovered by differential ribosome codon reading.

Loayza-Puch F, Rooijers K, Zijlstra J, Moumbeini B, Zaal EA, Oude Vrielink JF, Lopes R, Ugalde AP, Berkers CR, Agami R.

EMBO Rep. 2017 Apr;18(4):549-557. doi: 10.15252/embr.201744000. Epub 2017 Mar 8.


Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.

Ruprecht B, Zaal EA, Zecha J, Wu W, Berkers CR, Kuster B, Lemeer S.

Cancer Res. 2017 Apr 15;77(8):1842-1853. doi: 10.1158/0008-5472.CAN-16-2976. Epub 2017 Feb 16.


Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy.

Weijer R, Clavier S, Zaal EA, Pijls MM, van Kooten RT, Vermaas K, Leen R, Jongejan A, Moerland PD, van Kampen AH, van Kuilenburg AB, Berkers CR, Lemeer S, Heger M.

Cell Mol Life Sci. 2017 Mar;74(6):1133-1151. doi: 10.1007/s00018-016-2401-0. Epub 2016 Nov 1.


Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat.

Becher I, Werner T, Doce C, Zaal EA, Tögel I, Khan CA, Rueger A, Muelbaier M, Salzer E, Berkers CR, Fitzpatrick PF, Bantscheff M, Savitski MM.

Nat Chem Biol. 2016 Nov;12(11):908-910. doi: 10.1038/nchembio.2185. Epub 2016 Sep 26.


New Insight into the Catalytic Mechanism of Bacterial MraY from Enzyme Kinetics and Docking Studies.

Liu Y, Rodrigues JP, Bonvin AM, Zaal EA, Berkers CR, Heger M, Gawarecka K, Swiezewska E, Breukink E, Egmond MR.

J Biol Chem. 2016 Jul 15;291(29):15057-68. doi: 10.1074/jbc.M116.717884. Epub 2016 May 18.


Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Berkers CR, de Jong A, Schuurman KG, Linnemann C, Meiring HD, Janssen L, Neefjes JJ, Schumacher TN, Rodenko B, Ovaa H.

J Immunol. 2015 Nov 1;195(9):4085-95. doi: 10.4049/jimmunol.1402455. Epub 2015 Sep 23.


Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Berkers CR, de Jong A, Schuurman KG, Linnemann C, Geenevasen JA, Schumacher TN, Rodenko B, Ovaa H.

J Immunol. 2015 Nov 1;195(9):4075-84. doi: 10.4049/jimmunol.1402454. Epub 2015 Sep 23.


Evaluation of the educational value of a virtual reality TURP simulator according to a curriculum-based approach.

Tjiam IM, Berkers CH, Schout BM, Brinkman WM, Witjes JA, Scherpbier AJ, Hendrikx AJ, Koldewijn EL.

Simul Healthc. 2014 Oct;9(5):288-94. doi: 10.1097/SIH.0000000000000041.


Metabolic effect of TAp63α: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense.

D'Alessandro A, Amelio I, Berkers CR, Antonov A, Vousden KH, Melino G, Zolla L.

Oncotarget. 2014 Sep 15;5(17):7722-33.


Early adipogenesis is regulated through USP7-mediated deubiquitination of the histone acetyltransferase TIP60.

Gao Y, Koppen A, Rakhshandehroo M, Tasdelen I, van de Graaf SF, van Loosdregt J, van Beekum O, Hamers N, van Leenen D, Berkers CR, Berger R, Holstege FC, Coffer PJ, Brenkman AB, Ovaa H, Kalkhoven E.

Nat Commun. 2013;4:2656. doi: 10.1038/ncomms3656.


Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity.

van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE, Meerding J, Berkers CR, Barbi J, Gröne A, Sijts AJ, Maurice MM, Kalkhoven E, Prakken BJ, Ovaa H, Pan F, Zaiss DM, Coffer PJ.

Immunity. 2013 Aug 22;39(2):259-71. doi: 10.1016/j.immuni.2013.05.018.


Metabolic regulation by p53 family members.

Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH.

Cell Metab. 2013 Nov 5;18(5):617-33. doi: 10.1016/j.cmet.2013.06.019. Epub 2013 Aug 15. Review.


Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.

Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH.

Nature. 2013 Jan 24;493(7433):542-6. doi: 10.1038/nature11743. Epub 2012 Dec 16.


Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.

Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, Ovaa H.

Mol Pharm. 2012 May 7;9(5):1126-35. doi: 10.1021/mp2004143. Epub 2012 Apr 16.


Fluorescence-based proteasome activity profiling.

de Jong A, Schuurman KG, Rodenko B, Ovaa H, Berkers CR.

Methods Mol Biol. 2012;803:183-204. doi: 10.1007/978-1-61779-364-6_13.


Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease.

Nijholt DA, de Graaf TR, van Haastert ES, Oliveira AO, Berkers CR, Zwart R, Ovaa H, Baas F, Hoozemans JJ, Scheper W.

Cell Death Differ. 2011 Jun;18(6):1071-81. doi: 10.1038/cdd.2010.176. Epub 2011 Jan 21.


Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. Review.


Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry.

Pelletier S, Schuurman KG, Berkers CR, Ovaa H, Heck AJ, Raijmakers R.

Mol Biosyst. 2010 Aug;6(8):1450-3. doi: 10.1039/c004989a. Epub 2010 May 24.


Drug discovery and assay development in the ubiquitin-proteasome system.

Berkers CR, Ovaa H.

Biochem Soc Trans. 2010 Feb;38(Pt 1):14-20. doi: 10.1042/BST0380014.


Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.

Middeldorp J, Kamphuis W, Sluijs JA, Achoui D, Leenaars CH, Feenstra MG, van Tijn P, Fischer DF, Berkers C, Ovaa H, Quinlan RA, Hol EM.

FASEB J. 2009 Aug;23(8):2710-26. doi: 10.1096/fj.08-127696. Epub 2009 Mar 30.


Transpeptidation and reverse proteolysis and their consequences for immunity.

Berkers CR, de Jong A, Ovaa H, Rodenko B.

Int J Biochem Cell Biol. 2009 Jan;41(1):66-71. doi: 10.1016/j.biocel.2008.08.036. Epub 2008 Sep 4. Review.


Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.

Blood. 2008 Sep 15;112(6):2489-99. doi: 10.1182/blood-2007-08-104950. Epub 2008 Jun 18.


Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity.

Raijmakers R, Berkers CR, de Jong A, Ovaa H, Heck AJ, Mohammed S.

Mol Cell Proteomics. 2008 Sep;7(9):1755-62. doi: 10.1074/mcp.M800093-MCP200. Epub 2008 Jun 4.


Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, Hadrup SR, van Esch WJ, Heemskerk MH, Ovaa H, Schumacher TN.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3825-30. doi: 10.1073/pnas.0709717105. Epub 2008 Feb 28.


CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.


Profiling proteasome activity in tissue with fluorescent probes.

Berkers CR, van Leeuwen FW, Groothuis TA, Peperzak V, van Tilburg EW, Borst J, Neefjes JJ, Ovaa H.

Mol Pharm. 2007 Sep-Oct;4(5):739-48. Epub 2007 Aug 21.


A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo.

Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ, Witte MD, van der Linden WA, van den Nieuwendijk AM, Hofmann T, Berkers CR, van Leeuwen FW, Groothuis TA, Leeuwenburgh MA, Ovaa H, Neefjes JJ, Filippov DV, van der Marel GA, Dantuma NP, Overkleeft HS.

Chem Biol. 2006 Nov;13(11):1217-26.


Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.

Kraus M, Rückrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleeft H, Ovaa H, Driessen C.

Leukemia. 2007 Jan;21(1):84-92. Epub 2006 Oct 5.


Chemical proteomics profiling of proteasome activity.

Verdoes M, Berkers CR, Florea BI, van Swieten PF, Overkleeft HS, Ovaa H.

Methods Mol Biol. 2006;328:51-69.


A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.

Cancer Cell. 2005 Nov;8(5):407-19.


Immunotherapeutic potential for ceramide-based activators of iNKT cells.

Berkers CR, Ovaa H.

Trends Pharmacol Sci. 2005 May;26(5):252-7. Review.


Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.

Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ.

Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21.


Supplemental Content

Loading ...
Support Center